AMD - Age related Macular Degeneration

Improving Your Eye Care with Proactive Care
According to a published Ophthalmology study, 25% of age-related macular degeneration (AMD) cases go undetected - even with regular examinations using regular imaging tools. What’s more, additional studies show 78% of AMD patients do not seek treatment until their visual acuity is irreversibly damaged.

Earlier, More Accurate Detection
Structural changes (the appearance of drusen) in the retina are not always easily discernible. They often become evident only after AMD has progressed from a subclinical state. Impaired dark adaptation, as measured by AdaptDx™, is 90.6% sensitive and 90.5% specific in identifying the earliest onset of AMD. This makes AdaptDx more accurate than average testing for glaucoma (as the accuracy of visual field is only 83%). Being able to identify the earliest AMD biomarker with such accuracy will greatly improve your patients’ outcomes. It allows us to detect AMD at the subclinical stage, at least three years before drusen are visible, when action can be taken to slow disease progression and prevent vision loss.

Monitoring Disease Progression
Functional testing and structural examinations may be useful for monitoring disease progression. More frequent visits increase our opportunity to detect choroidal neovascularization (CNV) before visual acuity loss. The follow-up interval may be shortened to every three or four months for patients who are progressing rapidly or are at high risk of CNV.